基于外周血IL-6/STAT3信号通路探讨消癌平联合FOLFOX6方案治疗晚期直肠癌的疗效及其作用机制

doi:10.3969/j.issn.1001-8131.2025.03.003

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (572 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的基于外周血白细胞介素-6（IL-6）/信号转导因子和转录活化因子（STAT3）信号通路探讨消癌平联合FOLFOX6方案治疗晚期直肠癌的疗效及其作用机制。方法选取102例晚期直肠癌患者,采用随机数字表法将患者分为对照组和实验组,每组51例。对照组采用FOLFOX6方案化疗,实验组在对照组的基础上加用消癌平。观察并对比两组临床疗效、常规肿瘤标志物[癌胚抗原（CEA）、糖蛋白抗原199（CA199）]、细胞免疫功能指标、血清IL-6、STAT3水平。结果实验组客观缓解率（ORR）、疾病控制率（DCR）显著高于对照组（P<0.05）。治疗后,两组血清CEA、CA199水平下降,且实验组血清CEA、CA199水平低于对照组（P<0.05）。治疗后,两组CD8⁺下降,CD3⁺、CD4⁺、CD4⁺/CD8⁺升高,且实验组CD8⁺低于对照组,CD3⁺、CD4⁺、CD4⁺/CD8⁺高于对照组（P<0.05）。治疗后,两组血清IL-6、STAT3水平下降,且实验组血清IL-6、STAT3水平低于对照组（P<0.05）。结论消癌平联合FOLFOX6方案治疗晚期直肠癌,有助于提高临床疗效,降低血清肿瘤标志物水平,可能与调节机体免疫、调节外周血IL-6/STAT3信号通路有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李静
	胡煜月
	马慧利

关键词 ：白细胞介素-6/信号转导因子和转录活化因子信号通路, 消癌平, FOLFOX6方案, 晚期直肠癌, 疗效

Abstract：Objective To investigate the efficacy and mechanism of Xiaoaiping combined with FOLFOX6 regimen in the treatment of advanced rectal cancer based on peripheral blood interleukin-6(IL-6)/signal transduction factor and transcriptional activation factor(STAT3)signaling pathway. Methods 102 patients with advanced rectal cancer were divided into control group and experimental group by random number table method,with 51 cases in each group.The control group received FOLFOX6 chemotherapy,and the experimental group received Xiaocarpine on the basis of the control group.Clinical efficacy,conventional tumor markers [carcinoembryonic antigen(CEA),glycoprotein antigen 199(CA199)],cellular immune function,and peripheral blood IL-6/STAT3 signaling pathway related indexes[IL-6,STAT3] were observed and compared between the two groups. Results The Objective response rate(ORR)and disease control rate(DCR)of the experimental group were higher than those of the control group(P<0.05).After treatment,CEA and CA199 in experimental group were lower than those in control group(P<0.05).After treatment,CD8⁺ in the experimental group was lower than that in the control group,and CD3⁺,CD4⁺,CD4⁺/ CD8⁺ were higher than that in the control group(P<0.05).IL-6 and STAT3 in the experimental group were lower than those in the control group after treatment(P<0.05). Conclusion Xiaoaiping combined with FOLFOX6 regimen in the treatment of advanced rectal cancer is helpful to improve clinical efficacy and reduce the level of serum tumor markers,which may be related to the regulation of immunity and IL-6STAT3 signaling pathway in peripheral blood.

Key words： Interleukin-6 / signal transduction factor and transcription activation factor signaling pathway Xiaoaiping FOLFOX6 regimen Advanced rectal cancer Curative effect

收稿日期: 2025-02-26

PACS:

R735.3+7

基金资助:国家卫生健康委医药卫生科技发展研究中心课题（W2022ZT593）

引用本文:

李静, 胡煜月, 马慧利. 基于外周血IL-6/STAT3信号通路探讨消癌平联合FOLFOX6方案治疗晚期直肠癌的疗效及其作用机制[J]. 哈尔滨医药, 2025, 45(3): 11-14.
Li Jing, Hu Yuyue, Ma Huili. Investigate the Efficacy and Mechanism of Xiaoaiping Combined with FOLFOX6 Regimen in the Treatment of Advanced Rectal Cancer Based on IL-6/STAT3 Signaling Pathway in Peripheral Blood. journal1, 2025, 45(3): 11-14.

链接本文:

http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2025.03.003 或 http://www.hrbyybjb.org.cn/CN/Y2025/V45/I3/11

[1] Body A,Prenen H,Lam M,et al.Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges[J].Clin Colorectal Cancer,2021,20(1):29-41.
[2] Song SH,Park JS,Kang MK,et al.Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer[J].Int J Colorectal Dis,2021,36(6):1279-1286.
[3] 王登灿,陈焰烽,郑炜,等.加味八珍汤联合mFOLFOX6方案对晚期结直肠癌患者肿瘤标志物、免疫功能和外周血PI3K-Akt信号通路的影响[J].现代生物医学进展,2023,23(4):666-670,713.
[4] 匡子禹,刘可心,李杰.消癌平注射液联合一线化疗治疗晚期胃癌疗效的系统评价及Meta分析[J].天津中医药,2024,41(7):857-864.
[5] 宋学梅,管玲.晚期直肠癌的免疫治疗结合新辅助放化疗临床研究进展[J].生命科学仪器,2023,21(z2):104.
[6] 中华人民共和国国家卫生和计划生育委员会医政医管局,中华医学会肿瘤学分会.结直肠癌诊疗规范(2015年版)[J].中国实用外科杂志,2015,35(11):1177-1191.
[7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[8] 陈欣德,周帅,张茂容,等.消癌平注射液促进肺腺癌细胞凋亡的分子机制研究[J].皖南医学院学报,2022,41(3):209-213.
[9] 沙晓锋,张姣.安替可胶囊联合FOLFOX6方案对晚期胃癌患者血管生长因子、肿瘤标志物、生活质量的影响[J].现代中西医结合杂志,2020,29(15):1672-1675.
[10] 唐义东. 中药注射剂联合化疗治疗结直肠癌的网状Meta分析[D].沈阳:辽宁中医药大学,2019.
[11] 王祁民,孙利民,许剑峰.通关藤及其制剂消癌平抗肿瘤的相关性研究[J].临床误诊误治,2017,30(12):102-105.
[12] Jones AN,Scheurlen KM,Macleod A,et al.Obesity and Inflammatory Factors in the Progression of Early-Onset Colorectal Cancer[J].Cancers(Basel),2024,16(7):1403.
[13] 李双凤,黄家彦,韩笑,等.通关藤抗肿瘤主要成分及作用机制研究进展[J].药物评价研究,2023,46(1):187-197.